Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
$18.88
$18.88
$8.39
$19.12
$1.58B2.645.12 million shsN/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$71.88
-0.2%
$72.67
$31.46
$117.33
$7.62B0.151.19 million shs679,544 shs
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$1.19
-4.0%
$1.01
$0.69
$3.94
$235.86M0.74.75 million shs2.09 million shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$121.70
-2.6%
$109.40
$90.29
$129.90
$2.35B0.84116,645 shs106,482 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
-0.18%-1.06%+0.90%+4.75%+134.75%
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-4.03%+1.62%-1.65%+16.67%-49.58%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
-2.62%+6.40%+5.47%+16.72%+26.38%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
4.8161 of 5 stars
3.53.00.04.32.24.21.9
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
4.0161 of 5 stars
3.42.00.03.92.51.70.6
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
4.1075 of 5 stars
2.51.00.04.42.13.31.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
0.00
N/AN/AN/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
3.00
Buy$138.2592.33% Upside
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
2.80
Moderate Buy$7.00488.24% Upside
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
3.00
Buy$147.1720.93% Upside

Current Analyst Ratings Breakdown

Latest ESPR, CORT, ALDR, and LGND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
5/9/2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.00
5/7/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.00 ➝ $4.00
5/6/2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$135.00
5/6/2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$150.00 ➝ $145.00
4/25/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
4/25/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
4/17/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$4.00 ➝ $3.00
(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
$1.62M977.10N/AN/A$1.61 per share11.73
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$675.04M11.29$1.24 per share57.87$6.49 per share11.08
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$332.31M0.71$0.02 per share49.53($1.97) per share-0.60
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$167.13M14.05$1.61 per share75.74$43.95 per share2.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
-$296.43M-$4.87N/AN/AN/AN/A-226.13%-66.86%N/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$141.21M$1.1661.9738.85N/A19.33%20.40%16.64%8/4/2025 (Estimated)
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-$51.74M-$0.800.00N/AN/A-59.03%-0.91%-29.47%8/11/2025 (Estimated)
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
-$4.03M-$7.12N/A32.80N/A-73.07%-7.83%-6.92%8/5/2025 (Estimated)

Latest ESPR, CORT, ALDR, and LGND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$1.54N/AN/AN/A$43.87 millionN/A
8/4/2025Q2 2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$0.23N/AN/AN/AN/AN/A
5/8/2025Q1 2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$1.23$1.33+$0.10-$2.21$37.84 million$45.33 million
5/6/2025Q1 2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-$0.18-$0.21-$0.03-$0.21$54.97 million$65.00 million
5/5/2025Q1 2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$0.17$0.17N/A$0.17$177.93 million$157.21 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
N/AN/AN/AN/AN/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/AN/AN/AN/AN/A
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
N/AN/AN/AN/AN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
1.74
8.94
8.94
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/A
3.07
2.96
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
N/A
1.18
0.81
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/A
5.27
5.02
CompanyEmployeesShares OutstandingFree FloatOptionable
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
20283.84 millionN/AOptionable
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
300106.04 million83.99 millionOptionable
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
200198.20 million194.83 millionOptionable
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
8019.29 million17.94 millionOptionable

Recent News About These Companies

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alder Biopharmaceuticals stock logo

Alder Biopharmaceuticals NASDAQ:ALDR

Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.

Corcept Therapeutics stock logo

Corcept Therapeutics NASDAQ:CORT

$71.88 -0.13 (-0.18%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$71.35 -0.53 (-0.74%)
As of 07/11/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Esperion Therapeutics stock logo

Esperion Therapeutics NASDAQ:ESPR

$1.19 -0.05 (-4.03%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$1.20 +0.01 (+0.42%)
As of 07/11/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Ligand Pharmaceuticals stock logo

Ligand Pharmaceuticals NASDAQ:LGND

$121.70 -3.28 (-2.62%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$121.72 +0.02 (+0.02%)
As of 07/11/2025 07:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.